Numerous diseases are associated with abnormal or excessive angiogenesis, among them ocular diseases, cancer, rheumatoid arthritis, vascular malformations, diabetic nephropathy, and obesity, to name a few. Anti-angiogenic therapies have shown efficacy in ocular diseases and cancer. We are developing the next generation anti-angiogenic and anti-lymphangiogenic therapies that combine short therapeutic biomimetic peptides with delivery by biodegradable phagocytosis-resistant micro- and nanoparticles. We envision numerous applications of these novel therapeutics as monotherapies or in combination with existing drugs.